List of Rezurock drug patents
Rezurock is owned by Kadmon Pharms Llc.
Rezurock contains Belumosudil Mesylate.
Rezurock has a total of 5 drug patents out of which 0 drug patents have expired.
Rezurock was authorised for market use on 16 July, 2021.
Rezurock is available in tablet;oral dosage forms.
Rezurock can be used as for the treatment of chronic graft versus host disease, for the treatment of chronic graft versus hold disease, treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy.
Drug patent challenges can be filed against Rezurock from July, 2025.
The generics of Rezurock are possible to be released after 09 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(10 years from now) | |
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chronic graft-versus-host disease ( cgvhd) after failure of at least two prior lines of systemic therapy
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic